VelosBio to be Acquired by Merck…

 
June 19, 2013

Lumena Pharmaceuticals Inc. is converting a compound previously tested as a cholesterol-lowering agent into an experimental treatment for cholestatic liver diseases. The molecule inhibits a so-called transporter that normally helps the body recycle bile acid.